Conjunctival Autografting Alone or Combined With Subconjunctival Bevacizumab for Primary Pterygium Treatment.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 1
- 主要终点
- Pterygium recurrence
研究概览
简要总结
The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with primary pterygium
排除标准
- •Patients with diabetes mellitus
- •collagenopathies,
- •previous ocular surgeries,
- •pregnant or lactating patients
研究组 & 干预措施
One subconjunctival injection
Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
干预措施: Autoconjunctival grafting (Procedure)
One subconjunctival injection
Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
干预措施: Subconjuntival bevacizumab injection (Drug)
Two subconjuctival injections
Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
干预措施: Autoconjunctival grafting (Procedure)
Two subconjuctival injections
Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
干预措施: Subconjuntival bevacizumab injection (Drug)
Conventional treatment
Autoconjunctival grafting without subconjuntival bevacizumab injection
干预措施: Autoconjunctival grafting (Procedure)
结局指标
主要结局
Pterygium recurrence
时间窗: One point.
The pterygium recurrence is evaluated at one year postoperative
次要结局
- Conjunctival ischemia(Ischemia is measured at 24 h, 1 week, 15 days, six months and one year postoperative)